Log in

NASDAQ:ALKSAlkermes Stock Price, Forecast & News

$20.09
+0.46 (+2.34 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$19.49
Now: $20.09
$20.41
50-Day Range
$15.94
MA: $17.58
$19.76
52-Week Range
$11.98
Now: $20.09
$25.35
Volume2.98 million shs
Average Volume1.78 million shs
Market Capitalization$3.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More
Alkermes logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$0.60 per share
Book Value$6.89 per share

Profitability

Net Income$-196,620,000.00

Miscellaneous

Employees2,235
Market Cap$3.19 billion
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

How has Alkermes' stock been impacted by COVID-19 (Coronavirus)?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALKS stock has increased by 23.6% and is now trading at $20.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alkermes?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Alkermes.

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) posted its earnings results on Wednesday, April, 29th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.07. The company earned $246.20 million during the quarter, compared to analyst estimates of $230.53 million. Alkermes had a negative net margin of 11.63% and a positive return on equity of 4.99%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) EPS. View Alkermes' earnings history.

What price target have analysts set for ALKS?

12 analysts have issued twelve-month price objectives for Alkermes' stock. Their forecasts range from $16.00 to $28.00. On average, they expect Alkermes' share price to reach $21.17 in the next year. This suggests a possible upside of 5.4% from the stock's current price. View analysts' price targets for Alkermes.

Has Alkermes been receiving favorable news coverage?

News articles about ALKS stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alkermes earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Alkermes.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Who are Alkermes' key executives?

Alkermes' management team includes the following people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $20.09.

How big of a company is Alkermes?

Alkermes has a market capitalization of $3.19 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.